Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 119 articles: HTML format Text format

Single Articles

August 2018
1. CAO R, Teskey G, Islamoglu H, Abrahem R, et al
   Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
   Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01132.
   PubMed     Text format     Abstract available
   
   
   
2. ALFARISI O, Mave V, Gaikwad S, Sahasrabudhe T, et al
   The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.
   Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01383.
   PubMed     Text format     Abstract available
   
   
   
3. LUPIEN A, Vocat A, Foo CS, Blattes E, et al
   An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169).
   Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.00840.
   PubMed     Text format     Abstract available
   
   
   
4. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
   Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
   Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
   PubMed     Text format     Abstract available
   
   
   
5. KOSER CU, Heyckendorf J, Andres S, Olaru ID, et al
   Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".
   Antimicrob Agents Chemother. 2018;62.
   PubMed     Text format    
   
   
   
6. DOOKIE N, Naidoo K, Padayatchi N
   Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
   Antimicrob Agents Chemother. 2018;62.
   PubMed     Text format    
   
   
   July 2018
7. JAGIELSKI T, Bakula Z, Brzostek A, Minias A, et al
   Characterization of mutations conferring resistance to rifampicin in Mycobacterium tuberculosis clinical strains.
   Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.01093.
   PubMed     Text format     Abstract available
   
   
   
8. PELOQUIN CA, Phillips PPJ, Mitnick CD, Eisenach K, et al
   Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.
   Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770.
   PubMed     Text format     Abstract available
   
   
   
9. PITON J, Vocat A, Lupien A, Foo C, et al
   Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00681.
   PubMed     Text format     Abstract available
   
   
   
10. PIETERMAN ED, Te Brake LHM, de Knegt GJ, van der Meijden A, et al
    Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01354.
    PubMed     Text format     Abstract available
    
    
    
11. AGUILAR-PEREZ C, Gracia B, Rodrigues L, Vitoria A, et al
    Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00359.
    PubMed     Text format     Abstract available
    
    
    June 2018
12. RANCOITA PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, et al
    Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Jun 25. pii: AAC.00344.
    PubMed     Text format     Abstract available
    
    
    
13. HORITA Y, Alsultan A, Kwara A, Antwi S, et al
    Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations.
    Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00008.
    PubMed     Text format     Abstract available
    
    
    
14. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
    Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In vitro Assay.
    Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00856.
    PubMed     Text format     Abstract available
    
    
    
15. DRUSANO GL, Myrick J, Maynard M, Nole J, et al
    Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
    Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00221.
    PubMed     Text format     Abstract available
    
    
    May 2018
16. ZONG Z, Jing W, Shi J, Wen S, et al
    Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.
    Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00165.
    PubMed     Text format     Abstract available
    
    
    
17. SHOEN C, DeStefano M, Hafkin B, Cynamon M, et al
    In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00493.
    PubMed     Text format     Abstract available
    
    
    
18. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
    Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
    PubMed     Text format     Abstract available
    
    
    
19. KAUFMANN SHE
    Indole Propionic Acid: a Small Molecule Links between Gut Microbiota and Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    PubMed     Text format    
    
    
    April 2018
20. SHI W, Chen J, Zhang S, Zhang W, et al
    Identification of novel mutations in LprG (rv1411c), rv0521,rv3630, rv0010c, ppsC,cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00430.
    PubMed     Text format     Abstract available
    
    
    
21. BOOT M, Commandeur S, Subudhi AK, Bahira M, et al
    Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00083.
    PubMed     Text format     Abstract available
    
    
    
22. ZHENG H, Williams JT, Coulson GB, Haiderer ER, et al
    HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02459.
    PubMed     Text format     Abstract available
    
    
    
23. LIU Y, Pertinez H, Davies GR, Gillespie SH, et al
    Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00190.
    PubMed     Text format     Abstract available
    
    
    
24. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02359.
    PubMed     Text format     Abstract available
    
    
    
25. STEFAN MA, Ugur FS, Garcia GA
    SOURCE OF THE FITNESS DEFECT IN RIFAMYCIN-RESISTANT M. TUBERCULOSIS RNA POLYMERASE AND THE MECHANISM OF COMPENSATION BY MUTATIONS IN THE beta'-SUBUNIT.
    Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00164.
    PubMed     Text format     Abstract available
    
    
    February 2018
26. GUPTA R, Felix CR, Akerman MP, Akerman KJ, et al
    Gold(III) macrocycles and chelates targeting Mycobacterium tuberculosis and Mycobacterium abscessus: evidence for inhibition of topoisomerase 1A.
    Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.01696.
    PubMed     Text format     Abstract available
    
    
    
27. CHEN C, Gardete S, Jansen RS, Shetty A, et al
    Verapamil targets membrane energetics in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
    PubMed     Text format     Abstract available
    
    
    
28. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
    Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
    PubMed     Text format     Abstract available
    
    
    
29. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
    Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
    PubMed     Text format     Abstract available
    
    
    
30. ZUUR MA, Ghimire S, Bolhuis MS, Wessels AMA, et al
    The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.
    Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02250.
    PubMed     Text format     Abstract available
    
    
    
31. CHEN Y, Yuan Z, Shen X, Wu J, et al
    Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02259.
    PubMed     Text format     Abstract available
    
    
    
32. SAO EMANI C, Williams MJ, Wiid I, Baker B, et al
    Compounds with potential activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02236.
    PubMed     Text format     Abstract available
    
    
    January 2018
33. WANG Q, Pang Y, Jing W, Liu Y, et al
    Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02149.
    PubMed     Text format     Abstract available
    
    
    
34. HUO F, Luo J, Shi J, Zong Z, et al
    Increasing Prevalence of Rifampicin-Resistant Mycobacterium tuberculosis is Associated with the Transmission of Strains Harboring Compensatory Mutations in China: A 10-year Comparative Analysis.
    Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02303.
    PubMed     Text format     Abstract available
    
    
    
35. DIJKSTRA JA, van der Laan T, Akkerman OW, Bolhuis MS, et al
    In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01724.
    PubMed     Text format     Abstract available
    
    
    
36. YU X, Zeng X, Shi W, Hu Y, et al
    The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
    Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01824.
    PubMed     Text format     Abstract available
    
    
    
37. VILCHEZE C, Kim J, Jacobs WR Jr
    Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice.
    Antimicrob Agents Chemother. 2018 Jan 3. pii: AAC.02165.
    PubMed     Text format     Abstract available
    
    
    
38. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
    Antimicrob Agents Chemother. 2017;62.
    PubMed     Text format    
    
    
    December 2017
39. DOMPREH A, Tang X, Zhou J, Yang H, et al
    Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.02099.
    PubMed     Text format     Abstract available
    
    
    
40. AUNG WW, Ei PW, Nyunt WW, Htwe MM, et al
    Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar.
    Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.01984.
    PubMed     Text format     Abstract available
    
    
    
41. SARATHY JP, Via LE, Weiner D, Blanc L, et al
    Extreme drug tolerance of Mycobacterium tuberculosis in caseum.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.02266.
    PubMed     Text format     Abstract available
    
    
    
42. LEE H, Ahn S, Hwang NY, Jeon K, et al
    Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.01784.
    PubMed     Text format     Abstract available
    
    
    November 2017
43. DESHPANDE D, Srivastava S, Bendet P, Martin KR, et al
    On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.02232.
    PubMed     Text format     Abstract available
    
    
    
44. ABBADI BL, Villela AD, Rodrigues-Junior VS, Subtil FT, et al
    Revisiting activation of and the mechanism of resistance to the compound IQG-607 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 20. pii: AAC.02222.
    PubMed     Text format     Abstract available
    
    
    
45. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
    Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
    PubMed     Text format     Abstract available
    
    
    
46. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
    Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
    PubMed     Text format     Abstract available
    
    
    
47. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
    What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
    Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
    PubMed     Text format     Abstract available
    
    
    October 2017
48. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
    Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
    PubMed     Text format     Abstract available
    
    
    
49. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
    Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
    Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
    PubMed     Text format     Abstract available
    
    
    
50. BERUBE BJ, Parish T
    Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
    PubMed     Text format     Abstract available
    
    
    
51. GENESTET C, Ader F, Pichat C, Lina G, et al
    Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
    Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
    PubMed     Text format     Abstract available
    
    
    
52. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
    Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
    PubMed     Text format     Abstract available
    
    
    
53. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
    Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
    Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
    PubMed     Text format     Abstract available
    
    
    
54. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
    Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
    Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
    PubMed     Text format     Abstract available
    
    
    September 2017
55. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
    Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
    PubMed     Text format     Abstract available
    
    
    
56. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
    The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
    PubMed     Text format     Abstract available
    
    
    
57. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
    Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
    Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
    PubMed     Text format     Abstract available
    
    
    
58. HUSZAR S, Singh V, Polcicova A, Barath P, et al
    N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
    PubMed     Text format     Abstract available
    
    
    
59. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
    Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
    PubMed     Text format     Abstract available
    
    
    
60. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    
61. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
    Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    July 2017
62. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
    Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
    PubMed     Text format     Abstract available
    
    
    
63. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
    In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
    PubMed     Text format     Abstract available
    
    
    
64. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
    Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
    PubMed     Text format     Abstract available
    
    
    
65. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
    Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
    PubMed     Text format     Abstract available
    
    
    
66. PANG Y, Zong Z, Huo F, Jing W, et al
    In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
    Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
    PubMed     Text format     Abstract available
    
    
    
67. YANG SS, Hu YB, Wang XD, Gao YR, et al
    Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
    PubMed     Text format     Abstract available
    
    
    
68. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
    The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
    PubMed     Text format     Abstract available
    
    
    
69. ZIMMERMAN M, Lestner J, Prideaux B, O'Brien P, et al
    Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy.
    Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00924.
    PubMed     Text format     Abstract available
    
    
    
70. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
    A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
    Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
    PubMed     Text format     Abstract available
    
    
    June 2017
71. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
    The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
    PubMed     Text format     Abstract available
    
    
    
72. LI SY, Tasneen R, Tyagi S, Soni H, et al
    Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
    PubMed     Text format     Abstract available
    
    
    
73. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
    Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
    Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
    PubMed     Text format     Abstract available
    
    
    
74. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
    Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
    PubMed     Text format     Abstract available
    
    
    
75. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
    Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
    Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
    PubMed     Text format     Abstract available
    
    
    
76. ZHANG Y, Zhang J, Cui P, Zhang W, et al
    Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
    PubMed     Text format     Abstract available
    
    
    
77. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
    Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
    Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
    PubMed     Text format     Abstract available
    
    
    
78. FOFANA MO, Dowdy DW
    Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    
79. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
    Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    May 2017
80. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
    Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
    PubMed     Text format     Abstract available
    
    
    
81. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
    Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
    Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
    PubMed     Text format     Abstract available
    
    
    
82. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
    Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
    PubMed     Text format     Abstract available
    
    
    
83. MOREIRA W, Santhanakrishnan S, Ngan GJY, Low CB, et al
    Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available
    
    
    April 2017
84. NJIRE M, Wang N, Wang B, Tan Y, et al
    Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
    PubMed     Text format     Abstract available
    
    
    
85. VISWANATHAN G, Yadav S, Raghunand TR
    Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
    PubMed     Text format     Abstract available
    
    
    
86. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
    Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
    PubMed     Text format     Abstract available
    
    
    
87. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
    Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
    PubMed     Text format     Abstract available
    
    
    
88. JANG J, Kim R, Woo M, Jeong J, et al
    Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
    PubMed     Text format     Abstract available
    
    
    
89. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
    PubMed     Text format     Abstract available
    
    
    
90. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
    Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
    Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
    PubMed     Text format     Abstract available
    
    
    
91. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
    Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available
    
    
    March 2017
92. XU J, Wang B, Hu M, Huo F, et al
    Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
    PubMed     Text format     Abstract available
    
    
    
93. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
    Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
    PubMed     Text format     Abstract available
    
    
    
94. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
    Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format    
    
    
    February 2017
95. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
    Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
    Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
    PubMed     Text format     Abstract available
    
    
    
96. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
    Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
    PubMed     Text format     Abstract available
    
    
    
97. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
    Acquisition of rifampin resistance in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
    PubMed     Text format     Abstract available
    
    
    
98. CHOI SR, Britigan BE, Narayanasamy P
    Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
    PubMed     Text format     Abstract available
    
    
    January 2017
99. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
    Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
    Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
    PubMed     Text format     Abstract available
    
    
    
100. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
     Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
     Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
     PubMed     Text format     Abstract available
     
     
     
101. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
     Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
     PubMed     Text format     Abstract available
     
     
     
102. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
     Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
     PubMed     Text format     Abstract available
     
     
     
103. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
     Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
     PubMed     Text format     Abstract available
     
     
     December 2016
104. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
     Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
     Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
     PubMed     Text format     Abstract available
     
     
     
105. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
     Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
     Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
     PubMed     Text format     Abstract available
     
     
     
106. PANG Y, Zhang Z, Wang Y, Wang S, et al
     Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
     Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
     PubMed     Text format     Abstract available
     
     
     November 2016
107. BROSSIER F, Pham A, Bernard C, Aubry A, et al
     Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
     PubMed     Text format     Abstract available
     
     
     
108. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
     De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
     PubMed     Text format     Abstract available
     
     
     
109. YEE M, Gopal P, Dick T
     Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
     PubMed     Text format     Abstract available
     
     
     
110. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
     Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
     PubMed     Text format     Abstract available
     
     
     
111. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
     Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
     PubMed     Text format     Abstract available
     
     
     
112. ALFFENAAR JC, Akkerman OW, van Hest R
     Statin Adjunctive Therapy for Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2016;60:7004.
     PubMed     Text format    
     
     
     October 2016
113. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
     Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
     Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
     PubMed     Text format     Abstract available
     
     
     September 2016
114. WANG X, Yang S, Gu J, Deng J, et al
     Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
     PubMed     Text format     Abstract available
     
     
     
115. LI Y, Wang Y, Zhang Z, Gao H, et al
     Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
     PubMed     Text format     Abstract available
     
     
     
116. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
     Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
     PubMed     Text format     Abstract available
     
     
     May 2016
117. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
     Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
     Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
     PubMed     Text format     Abstract available
     
     
     January 2016
118. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
     The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
     Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
     PubMed     Text format     Abstract available
     
     
     November 2015
119. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
     Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
     Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: